US · Healthcare · Biotechnology
EPS came in at -0.03 against a street estimate of -0.03 — a beat of 0.0%.
Analysts rate Arbutus Biopharma Corp a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $5.37.
| Fund | Stake |
|---|---|
| Two Seas Capital LP | 12.11% |
| Morgan Stanley - Brokerage Accounts | 11.55% |
| Whitefort Capital Management, LP. | 10.30% |
| BlackRock Inc | 8.98% |
| State Street Corp | 5.13% |
| Rubric Capital Management LP | 4.91% |
| Vanguard Capital Management, LLC | 4.57% |
| Barclays PLC | 2.75% |
| Document | Date |
|---|---|
| Company announcement · Q3 2026 ARBUTUS BIOPHARMA CORPORATION – FORM 8-K SUMMARY HEADLINE NUMBERS • Company announced plans for modified Dutch auction tender offer to repurchase up | 2026-08-21 |
| Quarterly report · Q2 2026 ARBUTUS BIOPHARMA CORPORATION – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Six-month net income: $164.6 million (vs. $22.0 million loss in H1 2025) • Q | 2026-08-12 |
| Results announced · Q3 2026 ARBUTUS BIOPHARMA Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Cash position: $92.6 million in cash, cash equivalents and marketable securit | 2026-08-12 |
| Board / officer change · Q3 2026 ARBUTUS BIOPHARMA CORPORATION - FORM 8-K SUMMARY HEADLINE NUMBERS • Company received $178 million as its share of a $950 million noncontingent lump | 2026-07-16 |
| Board / officer change · Q2 2026 ARBUTUS BIOPHARMA CORPORATION - FORM 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • Arbutus Biopharma Corporation held its 2026 Annual General and Spec | 2026-05-27 |
| Quarterly report · Q1 2026 ARBUTUS BIOPHARMA CORP - Q1 2026 SUMMARY HEADLINE NUMBERS • Net income: $169.7 million for Q1 2026 vs. net loss of $24.5 million for Q1 2025 • Earni | 2026-05-13 |
| Proxy statement · Q2 2026 ARBUTUS BIOPHARMA CORPORATION – 2026 PROXY STATEMENT SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Elect 5 directors to serve until 2027 Ann | 2026-04-14 |
| Annual report FY2025 ARBUTUS BIOPHARMA CORPORATION – 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Market capitalization (as of June 30, 2025): $472.1 million • S | 2026-03-23 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Arbutus Biopharma Corp — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.